OccuLogix, Inc. (USA)
(Public, NASDAQ:TEAR) Watch this stockFind more results for
Nasdaq:RHEO
Advertisement
Events
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -1054.64% | -2040.96% |
| Operating margin | -1777.32% | -2251.63% |
| EBITD margin | - | -1969.93% |
| Return on average assets | -37.32% | -65.24% |
| Return on average equity | -48.61% | -206.87% |
| Employees | 15 | - |
Address
2600 Skymark Avenue, Unit 9 Suite 103
Mississauga, ON L4W 5B2
Canada
+1-905-6020887 (Phone)
+1-905-6027623 (Fax)
Mississauga, ON L4W 5B2
Canada
+1-905-6020887 (Phone)
+1-905-6027623 (Fax)
Website links
Company website:
http://www.occulogix.com/
http://www.occulogix.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
OccuLogix, Inc. (USA) discussions
View all discussions »Description
OccuLogix, Inc. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System enables the rapid measurement of tear osmolarity in the doctor's office, a quantitative and highly specific biomarker that has been shown to correlate with DED. On October 6, 2008, the Company acquired the remaining minority interest in TearLab, Inc.
Officers and directors
| Elias Vamvakas | Chairman of the Board, Interim Chief Executive Officer, Secretary | |
| William G. Dumencu CA | Chief Financial Officer, Treasurer | |
| Benjamin Sullivan Ph.D. | Chief Scientific Officer | |
| Thomas N. Davidson | Director | |
| Richard L. Lindstrom M.D. | Director | |
| Adrienne L. Graves Ph.D. | Director | |
| Donald Clark Rindell | Director | |
| Anthony E. Altig | Director |